ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors.
2 registry-linked trialsOpen access · greenAbstract readClinical Trial, Phase I
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 277 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
277citing papers in PubMed, 2 pooled it
17.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With Advanced, Unresectable Cervical Cancer With Disease Progression During or After Platinum-Containing Chemotherapy
Who cites it
277 citing papers in PubMed, 2 syntheses or guidelines pooled it, 411 citations in OpenAlex.
- Laryngeal squamous cell carcinoma: a functional "two-hit" model of papillomavirus-Epstein-Barr virus synergistic carcinogenesis.Frontiers in cellular and infection microbiology · 2026Pooled it
- Checkpoint inhibitors as dual immunotherapy in advanced non-small cell lung cancer: a meta-analysis.Frontiers in oncology · 2023Pooled it
- The quadruple immunotherapy for colorectal cancer (QuICC) trial for mismatch repair-proficient metastatic colorectal cancer.The oncologist · 2026Trial
- Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer.Signal transduction and targeted therapy · 2024Trial
- Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliary tract cancer or pancreatic ductal adenocarcinoma: a phase II trial.Signal transduction and targeted therapy · 2024Trial
- Immunotherapy in cervical cancer: From the view of scientometric analysis and clinical trials.Frontiers in immunology · 2023Trial
- Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer.Journal for immunotherapy of cancer · 2021Trial
- Development of a novel immune infiltration-based gene signature to predict prognosis and immunotherapy response of a novel anti-PD-L1/TGF-β bifunctional fusion protein in recurrent cervical cancer.Human vaccines & immunotherapeutics · 2026Article
- Resistance to PD-1/PD-L1 blockade: Mechanism and pharmacological strategies.Pharmacological research · 2026Review
- [Novel therapeutic strategies for liver metastases driven by the common microenvironment].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- Cold and hot tumors: immunological determinants, cancer-immunity cycle dysregulation, and nanotechnology-driven therapeutic approaches.Molecular biomedicine · 2026Review
- Matrix Architecture and Integrin Branch Balance Distinguish Immune-Regulatory States in Clear Cell Renal Cell Carcinoma.Current issues in molecular biology · 2026Article
- Ecosystem-matched reprogramming of the tumor-immune microenvironment to overcome cancer immunotherapy resistance.Molecular cancer · 2026Review
- [Efficacy of CD4/TGF-β bispecific antibody in a mouse model of peritoneal metastasis of malignant melanoma].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- TGF-β inhibition enhances anti-tumor immunity and sensitizes PD-1 blockade therapy of bone marrow-derived myofibroblasts-induced "immunotherapy resistance" tumor model.Cancer immunology, immunotherapy : CII · 2026Article
- Phase I study of Y101D, a bispecific antibody targeting PD-L1 and TGF-β in patients with advanced solid tumors.The oncologist · 2026Article
- Therapeutic Strategies Targeting the Tumor-Stromal Microenvironment in Colorectal Cancer: A Narrative Review.Targeted oncology · 2026Review
- Heterogeneity and plasticity of cancer-associated fibroblasts.Nature cancer · 2026Review
- Spatial single-cell multi-omics characterization of the tumor microenvironment heterogeneity by HER-2 expression status in gastric cancer.Molecular cancer · 2026Article
- Potent antitumor activity through dual targeting of PD-L1 and TGF-β pathways in the glioma tumor microenvironment.Journal for immunotherapy of cancer · 2026Article
217 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 1 country.
Julius StraussLaboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, Maryland.
Christopher R HeeryLaboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, Maryland.
Jeffrey SchlomLaboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, Maryland.
Ravi A MadanGenitourinary Malignancies Branch, National Cancer Institute, NIH, Bethesda, Maryland.
Liang CaoMolecular Targets Core, Genetics Branch, National Cancer Institute, NIH, Bethesda, Maryland.
Zhigang KangMolecular Targets Core, Genetics Branch, National Cancer Institute, NIH, Bethesda, Maryland.
Elizabeth LampingOffice of Research Nursing, National Cancer Institute, NIH, Bethesda, Maryland.
Jennifer L MartéGenitourinary Malignancies Branch, National Cancer Institute, NIH, Bethesda, Maryland.
Renee N DonahueLaboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, Maryland.
Italia GrengaLaboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, Maryland.
Lisa CordesPharmacy Department, Clinical Center, NIH, Bethesda, Maryland.
Olaf ChristensenEMD Serono, Billerica, Massachusetts.
Lisa MahnkeEMD Serono, Billerica, Massachusetts.
Christoph HelwigMerck KGaA, Darmstadt, Germany.
James L GulleyGenitourinary Malignancies Branch, National Cancer Institute, NIH, Bethesda, Maryland. gulleyj@mail.nih.gov.
Merck (Germany) · DE
Funding
Design, Develop, Validate, and Implement Biomarkers for Clinical InvestigationsZICBC010981 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HESELMEYER, KERSTIN · 2009 to 2025
$11.7MClinical trials employing cancer vaccine combination therapiesZIABC010945 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GULLEY, JAMES L. · 2009 to 2022
$9.6MCancer Immunotherapy Clinical TrialsZIABC011547 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI STRAUSS, JULIUS · 2014 to 2023
$8.1MCCR NIH HHS HHSN261200800001CIntramural NIH HHS ZIA BC010945NCI NIH HHS HHSN261200800001E
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAntibodies, BispecificAntineoplastic Agents, ImmunologicalB7-H1 AntigenCombined Modality TherapyFemaleHumansMaleMiddle AgedMolecular Targeted TherapyNeoplasm MetastasisNeoplasmsNeoplasm StagingRetreatmentTransforming Growth Factor betaAntibodies, BispecificAntineoplastic Agents, ImmunologicalB7-H1 AntigenCD274 protein, humanTransforming Growth Factor beta
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT02517398ClinicalTrials.gov
NCT04246489ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.